Martin Reincke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7093759/publications.pdf Version: 2024-02-01

	30070	30922
11,816	54	102
citations	h-index	g-index
172	172	6244
docs citations	times ranked	citing authors
	citations 172	11,816 54 citations h-index 172 172

#	Article	IF	CITATIONS
1	The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1889-1916.	3.6	1,921
2	Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes and Endocrinology,the, 2017, 5, 689-699.	11.4	595
3	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nature Genetics, 2013, 45, 440-444.	21.4	460
4	Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nature Genetics, 2015, 47, 31-38.	21.4	450
5	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
6	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	3.6	310
7	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension, 2014, 64, 354-361.	2.7	248
8	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	2.7	246
9	Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624.	2.7	235
10	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
11	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	5.0	187
12	Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3939-3948.	3.6	163
13	The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E997-E1004.	3.6	163
14	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. Hypertension, 2014, 63, 188-195.	2.7	151
15	Automated Chemiluminescence-Immunoassay for Aldosterone during Dynamic Testing: Comparison to Radioimmunoassays with and without Extraction Steps. Clinical Chemistry, 2006, 52, 1749-1755.	3.2	136
16	Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes and Endocrinology,the, 2015, 3, 296-303.	11.4	134
17	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	11.4	129
18	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. Hypertension, 2016, 67, 139-145.	2.7	127

#	Article	IF	CITATIONS
19	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
20	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4686-4692.	3.6	123
21	Mass Spectrometry–Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. Clinical Chemistry, 2016, 62, 514-524.	3.2	123
22	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clinica Chimica Acta, 2017, 470, 115-124.	1.1	116
23	Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry. European Journal of Endocrinology, 2015, 173, 665-675.	3.7	115
24	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	3.7	114
25	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 2012, 167, 35-42.	3.7	111
26	Diagnosis and treatment of primary aldosteronism. Lancet Diabetes and Endocrinology,the, 2021, 9, 876-892.	11.4	106
27	Subclinical hypercortisolism: a state, a syndrome, or a disease?. European Journal of Endocrinology, 2015, 173, M61-M71.	3.7	104
28	Landscape of somatic mutations in sporadic CH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	3.7	100
29	Adrenal Function After Adrenalectomy for Subclinical Hypercortisolism and Cushing's Syndrome: A Systematic Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2637-2645.	3.6	99
30	Clinical Outcomes of 1625 Patients With Primary Aldosteronism Subtyped With Adrenal Vein Sampling. Hypertension, 2019, 74, 800-808.	2.7	97
31	Age Below 40 or a Recently Proposed Clinical Prediction Score Cannot Bypass Adrenal Venous Sampling in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1035-E1039.	3.6	95
32	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	2.7	94
33	Adrenal vein sampling using rapid cortisol assays in primary aldosteronism is useful in centers with low success rates. European Journal of Endocrinology, 2011, 165, 301-306.	3.7	93
34	MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. European Journal of Endocrinology, 2018, 179, R19-R29.	3.7	89
35	Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. European Journal of Endocrinology, 2014, 171, 209-215.	3.7	83
36	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	20.1	81

#	Article	IF	CITATIONS
37	Aldosterone Excess Impairs First Phase Insulin Secretion in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2513-2520.	3.6	80
38	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
39	A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome. European Journal of Endocrinology, 2015, 173, M23-M32.	3.7	74
40	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.5	74
41	Impaired Glucose Metabolism in Primary Aldosteronism Is Associated With Cortisol Cosecretion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3192-3202.	3.6	72
42	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. Clinical Chemistry, 2018, 64, 586-596.	3.2	70
43	Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	3.6	69
44	The Primary Aldosteronism Surgical Outcome Score for the Prediction of Clinical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Annals of Surgery, 2020, 272, 1125-1132.	4.2	66
45	Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clinical Endocrinology, 1997, 46, 619-626.	2.4	65
46	Time to Recovery of Adrenal Function After Curative Surgery for Cushing's Syndrome Depends on Etiology. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1300-1308.	3.6	65
47	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	3.6	65
48	Driver mutations in USP8 wild-type Cushing's disease. Neuro-Oncology, 2019, 21, 1273-1283.	1.2	65
49	Subtyping of Primary Aldosteronism in the AVIS-2 Study: Assessment of Selectivity and Lateralization. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2042-2052.	3.6	65
50	Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension, 2016, 67, 146-152.	2.7	63
51	Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. World Journal of Biological Psychiatry, 2014, 15, 26-35.	2.6	62
52	ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing's syndrome. European Journal of Endocrinology, 2020, 183, G1-G7.	3.7	61
53	Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. European Journal of Endocrinology, 2013, 168, 75-81.	3.7	58
54	Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4397-4402.	3.6	58

#	Article	IF	CITATIONS
55	Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. European Journal of Endocrinology, 2017, 176, 737-746.	3.7	57
56	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes and Endocrinology,the, 2018, 6, 404-415.	11.4	56
57	The <i><scp>USP</scp>8</i> mutational status may predict longâ€ŧerm remission in patients with Cushing's disease. Clinical Endocrinology, 2018, 89, 454-458.	2.4	56
58	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. JAMA Network Open, 2020, 3, e2016209.	5.9	53
59	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	2.7	51
60	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2985-2993.	3.6	49
61	Quality of life in patients with primary aldosteronism: Gender differences in untreated and long-term treated patients and associations with treatment and aldosterone. Journal of Psychiatric Research, 2012, 46, 1650-1654.	3.1	47
62	Cortisol Excess in Patients With Primary Aldosteronism Impacts Left Ventricular Hypertrophy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4543-4552.	3.6	47
63	Development and Validation of Prediction Models for Subtype Diagnosis of Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3706-e3717.	3.6	47
64	Neuroendocrine Dysfunction in African Trypanosomiasis: The Role of Cytokines ^a . Annals of the New York Academy of Sciences, 1998, 840, 809-821.	3.8	46
65	Decoding the genetic basis of Cushing's disease: USP8 in the spotlight. European Journal of Endocrinology, 2015, 173, M73-M83.	3.7	46
66	Toward a Diagnostic Score in Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 766.	3.5	46
67	Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 621-630.	2.2	45
68	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3010-3017.	3.6	43
69	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	3.7	42
70	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. Science Advances, 2021, 7, .	10.3	42
71	Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4686-4692.	3.6	42
72	Linear and Volumetric Evaluation of the Adrenal Gland—MDCT-Based Measurements of the Adrenals. Academic Radiology, 2014, 21, 1465-1474.	2.5	41

#	Article	IF	CITATIONS
73	Worse Healthâ€Related Quality of Life at longâ€ŧerm followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp> . Clinical Endocrinology, 2018, 88, 787-798.	2.4	40
74	Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment. Endocrine, 2020, 70, 218-231.	2.3	40
75	Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldn't Ignore It!. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1-4.	3.6	39
76	DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?. European Journal of Endocrinology, 2018, 178, R1-R9.	3.7	39
77	Approach to the Patient Treated with Steroidogenesis Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2114-2123.	3.6	39
78	Adrenal Insufficiency After Unilateral Adrenalectomy in Primary Aldosteronism: Long-Term Outcome and Clinical Impact. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5658-5664.	3.6	37
79	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. European Journal of Endocrinology, 2018, 178, 57-63.	3.7	37
80	Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension, 2017, 70, 875-881.	2.7	35
81	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4331-4340.	3.6	35
82	The role of regulated necrosis in endocrine diseases. Nature Reviews Endocrinology, 2021, 17, 497-510.	9.6	35
83	Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension, 2021, 78, 738-746.	2.7	35
84	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Cell Reports, 2021, 37, 110169.	6.4	34
85	Mass Spectrometry Imaging Establishes 2 Distinct Metabolic Phenotypes of Aldosterone-Producing Cell Clusters in Primary Aldosteronism. Hypertension, 2020, 75, 634-644.	2.7	33
86	Disordered CYP11B2 Expression in Primary Aldosteronism. Hormone and Metabolic Research, 2017, 49, 957-962.	1.5	31
87	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
88	Longâ€ŧerm morbidity and mortality in patients with Cushing's syndrome. Journal of Neuroendocrinology, 2022, 34, e13113.	2.6	31
89	Histological Characterization of Aldosterone-producing Adrenocortical Adenomas with Different Somatic Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e282-e289.	3.6	29
90	Persisting Muscle Dysfunction in Cushing's Syndrome Despite Biochemical Remission. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4490-e4498.	3.6	29

#	Article	IF	CITATIONS
91	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. Journal of Steroid Biochemistry and Molecular Biology, 2019, 189, 274-282.	2.5	28
92	Genetics of Cushing's disease. Clinical Endocrinology, 2018, 88, 3-12.	2.4	27
93	Primary Aldosteronism. Hypertension, 2019, 74, 809-816.	2.7	27
94	In situ metabolomics of aldosterone-producing adenomas. JCI Insight, 2019, 4, .	5.0	27
95	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2027-e2036.	3.6	27
96	Post-saline infusion test aldosterone levels indicate severity and outcome in primary aldosteronism. European Journal of Endocrinology, 2015, 172, 443-450.	3.7	26
97	Cushing's syndrome: a model for sarcopenic obesity. Endocrine, 2017, 57, 481-485.	2.3	26
98	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	3.7	26
99	Adrenal Venous Sampling–Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1400-e1407.	3.6	25
100	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology, 2019, 160, 2600-2617.	2.8	24
101	Tumor-Directed Therapeutic Targets in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 925-933.	3.6	24
102	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. European Journal of Endocrinology, 2017, 177, 227-237.	3.7	23
103	Sarcopenia – Endocrinological and Neurological Aspects. Experimental and Clinical Endocrinology and Diabetes, 2019, 6, 8-22.	1.2	23
104	Lack of influence of somatic mutations on steroid gradients during adrenal vein sampling in aldosterone-producing adenoma patients. European Journal of Endocrinology, 2013, 169, 657-663.	3.7	22
105	Thyroid dysfunction in African trypanosomiasis: a possible role for inflammatory cytokines. Clinical Endocrinology, 1993, 39, 455-461.	2.4	21
106	Circulating miRNA Expression Profiling in Primary Aldosteronism. Frontiers in Endocrinology, 2019, 10, 739.	3.5	21
107	Therapeutic options after surgical failure in Cushing's disease: A critical review. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101270.	4.7	20
108	The potential pathophysiological role of aldosterone and the mineralocorticoid receptor in anxiety and depression – Lessons from primary aldosteronism. Journal of Psychiatric Research, 2020, 130, 82-88.	3.1	20

#	Article	IF	CITATIONS
109	Nomogram-Based Preoperative Score for Predicting Clinical Outcome in Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4382-e4392.	3.6	20
110	Adrenal Surgery for Cushing's Syndrome. Endocrinology and Metabolism Clinics of North America, 2018, 47, 385-394.	3.2	19
111	Proteomic Landscape of Aldosterone-Producing Adenoma. Hypertension, 2019, 73, 469-480.	2.7	19
112	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
113	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
114	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	3.7	19
115	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1181-e1192.	3.6	19
116	The impact of Connshing's syndrome - mild cortisol excess in primary aldosteronism drives diabetes risk. Journal of Hypertension, 2017, 35, 2548.	0.5	18
117	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	3.6	18
118	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. European Journal of Endocrinology, 2022, 187, 123-134.	3.7	18
119	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism—a Review. Current Hypertension Reports, 2019, 21, 77.	3.5	17
120	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3374-e3383.	3.6	17
121	Cushing Syndrome Associated Myopathy: It Is Time for a Change. Endocrinology and Metabolism, 2021, 36, 564-571.	3.0	16
122	Development of a Prediction Score to Avoid Confirmatory Testing in Patients With Suspected Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1708-1716.	3.6	16
123	Treatment of Unilateral PA by Adrenalectomy: Potential Reasons for Incomplete Biochemical Cure. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 100-108.	1.2	15
124	Expression and mutational status of USP8 in tumors causing ectopic ACTH secretion syndrome. Endocrine-Related Cancer, 2017, 24, L73-L77.	3.1	14
125	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 305-313.	3.6	14
126	Altered Taste Perception for Sodium Chloride in Patients With Primary Aldosteronism. Hypertension, 2021, 77, 1332-1340.	2.7	14

#	Article	IF	CITATIONS
127	Pathophysiology and histopathology of primary aldosteronism. Trends in Endocrinology and Metabolism, 2022, 33, 36-49.	7.1	14
128	Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3723-e3730.	3.6	14
129	Pathogenesis of Cushing Disease: An Update on the Genetics of Corticotropinomas. Endocrine Practice, 2018, 24, 907-914.	2.1	13
130	Patients with low IGF-I after curative surgery for Cushing's syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. European Journal of Endocrinology, 2021, 184, 813-821.	3.7	13
131	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 233-250.	5.7	13
132	IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1698-1707.	3.6	13
133	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. Endocrine-Related Cancer, 2020, 27, 403-413.	3.1	13
134	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	2.7	13
135	Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e484-e493.	3.6	12
136	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	3.1	12
137	The NETting of pituitary adenoma: a gland illusion. Pituitary, 2022, 25, 349-351.	2.9	12
138	Circulating microRNA Expression in Cushing's Syndrome. Frontiers in Endocrinology, 2021, 12, 620012.	3.5	11
139	Safety of medical adjustment and confirmatory testing in the diagnostic work-up of primary aldosteronism. European Journal of Endocrinology, 2019, 181, 421-428.	3.7	11
140	Genomic epidemiology reveals multiple introductions of SARS-CoV-2 followed by community and nosocomial spread, Germany, February to May 2020. Eurosurveillance, 2021, 26, .	7.0	11
141	Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocrine-Related Cancer, 2022, 29, 503-511.	3.1	11
142	Genetic and Potential Autoimmune Triggers of Primary Aldosteronism. Hypertension, 2015, 66, 248-253.	2.7	10
143	Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine, 2020, 69, 625-633.	2.3	10
144	The metabolic phenotype of patients with primary aldosteronism: impact of subtype and sex – a multicenter-study of 3566 Caucasian and Asian subjects. European Journal of Endocrinology, 2022, 187, 361-372.	3.7	9

#	Article	IF	CITATIONS
145	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. Clinica Chimica Acta, 2020, 507, 98-103.	1.1	8
146	BEX1 Is Differentially Expressed in Aldosterone-Producing Adenomas and Protects Human Adrenocortical Cells From Ferroptosis. Hypertension, 2021, 77, 1647-1658.	2.7	8
147	Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test. European Journal of Endocrinology, 2020, 183, 191-201.	3.7	8
148	Treatment of Primary Aldosteronism With mTORC1 Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4703-4714.	3.6	7
149	What is the role of medical therapy in adrenal-dependent Cushing's syndrome?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101376.	4.7	7
150	Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia. Journal of the Endocrine Society, 2021, 5, bvaa162.	0.2	7
151	Genomics in Cushing's Disease: The Dawn of a New Era. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2455-e2456.	3.6	7
152	Autonomous Cortisol Secretion Influences Psychopathological Symptoms in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2423-e2433.	3.6	7
153	Medullary thyroid cancer with ectopic Cushing's syndrome: A multicentre case series. Clinical Endocrinology, 2022, 96, 847-856.	2.4	7
154	The Impact of Glucocorticoid Co-Secretion in Primary Aldosteronism on Thyroid Autoantibody Titers During the Course of Disease. Hormone and Metabolic Research, 2020, 52, 404-411.	1.5	6
155	Characteristics of preoperative steroid profiles and glucose metabolism in patients with primary aldosteronism developing adrenal insufficiency after adrenalectomy. Scientific Reports, 2021, 11, 11181.	3.3	6
156	Primary Aldosteronism: Metabolic Reprogramming and the Pathogenesis of Aldosterone-Producing Adenomas. Cancers, 2021, 13, 3716.	3.7	6
157	Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study. Frontiers in Endocrinology, 2021, 12, 765067.	3.5	5
158	Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1262-E1269.	3.6	4
159	Primary aldosteronism long-term outcome: Medical versus surgical therapy. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 132-138.	1.4	4
160	Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis. Frontiers in Endocrinology, 2020, 11, 574.	3.5	4
161	Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia. Medicina (Lithuania), 2020, 56, 34.	2.0	4
162	Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2473-2482.	3.6	4

#	Article	IF	CITATIONS
163	Perspectives of the European Society of Endocrinology (ESE) and the European Society of Paediatric Endocrinology (ESPE) on rare endocrine disease. Endocrine, 2021, 71, 539-541.	2.3	3
164	Timeline of Advances in Genetics of Primary Aldosteronism. Experientia Supplementum (2012), 2019, 111, 213-243.	0.9	3
165	Metformin: the white knight fighting corticosteroid side-effects. Lancet Diabetes and Endocrinology,the, 2020, 8, 258-259.	11.4	2
166	Improving Diagnostic Efficiency with Frequency Double-Trees and Frequency Nets in Bayesian Reasoning. MDM Policy and Practice, 2022, 7, 238146832210866.	0.9	2
167	True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives European Journal of Endocrinology, 2022, , .	3.7	2
168	Response to Letter to the Editor: "Impaired Glucose Metabolism in Primary Aldosteronism Is Associated with Cortisol Cosecretion― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e916-e917.	3.6	1
169	Response to the Letter to the Editor: "Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomyâ€: Journal of Clinical Endocrinology and Metabolism, 2020, 105, e922-e923.	3.6	Ο